These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 29688121)

  • 1. Serological responses to rotavirus NSP2 following administration of RV3-BB human neonatal rotavirus vaccine.
    Cowley D; Pavlic D; Bogdanovic-Sakran N; Boniface K; Kirkwood CD; Bines JE
    Hum Vaccin Immunother; 2018; 14(8):2082-2087. PubMed ID: 29688121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rotavirus shedding following administration of RV3-BB human neonatal rotavirus vaccine.
    Cowley D; Boniface K; Bogdanovic-Sakran N; Kirkwood CD; Bines JE
    Hum Vaccin Immunother; 2017 Aug; 13(8):1908-1915. PubMed ID: 28481726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial.
    Bines JE; Danchin M; Jackson P; Handley A; Watts E; Lee KJ; West A; Cowley D; Chen MY; Barnes GL; Justice F; Buttery JP; Carlin JB; Bishop RF; Taylor B; Kirkwood CD;
    Lancet Infect Dis; 2015 Dec; 15(12):1389-97. PubMed ID: 26318715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rotavirus specific maternal antibodies and immune response to RV3-BB neonatal rotavirus vaccine in New Zealand.
    Chen MY; Kirkwood CD; Bines J; Cowley D; Pavlic D; Lee KJ; Orsini F; Watts E; Barnes G; Danchin M
    Hum Vaccin Immunother; 2017 May; 13(5):1126-1135. PubMed ID: 28059609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of RV3-BB rotavirus vaccine: a human neonatal rotavirus vaccine.
    Danchin M; Kirkwood CD; Lee KJ; Bishop RF; Watts E; Justice FA; Clifford V; Cowley D; Buttery JP; Bines JE
    Vaccine; 2013 May; 31(23):2610-6. PubMed ID: 23597719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of four doses of oral poliovirus vaccine when co-administered with the human neonatal rotavirus vaccine (RV3-BB).
    Cowley D; Sari RM; Handley A; Watts E; Bachtiar NS; At Thobari J; Satria CD; Bogdanovic-Sakran N; Nirwati H; Orsini F; Lee KJ; Kirkwood CD; Soenarto Y; Bines JE
    Vaccine; 2019 Nov; 37(49):7233-7239. PubMed ID: 31607604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neonatal rotavirus vaccine (RV3-BB) immunogenicity and safety in a neonatal and infant administration schedule in Malawi: a randomised, double-blind, four-arm parallel group dose-ranging study.
    Witte D; Handley A; Jere KC; Bogandovic-Sakran N; Mpakiza A; Turner A; Pavlic D; Boniface K; Mandolo J; Ong DS; Bonnici R; Justice F; Bar-Zeev N; Iturriza-Gomara M; Ackland J; Donato CM; Cowley D; Barnes G; Cunliffe NA; Bines JE
    Lancet Infect Dis; 2022 May; 22(5):668-678. PubMed ID: 35065683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rotavirus-Specific Maternal Serum Antibodies and Vaccine Responses to RV3-BB Rotavirus Vaccine Administered in a Neonatal or Infant Schedule in Malawi.
    Morgan B; Lyons EA; Handley A; Bogdanovic-Sakran N; Pavlic D; Witte D; Mandolo J; Turner A; Jere KC; Justice F; Ong DS; Bonnici R; Boniface K; Donato CM; Mpakiza A; Meyer A; Bar-Zeev N; Iturriza-Gomara M; Cunliffe NA; Danchin M; Bines JE
    Viruses; 2024 Sep; 16(9):. PubMed ID: 39339964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human Neonatal Rotavirus Vaccine (RV3-BB) to Target Rotavirus from Birth.
    Bines JE; At Thobari J; Satria CD; Handley A; Watts E; Cowley D; Nirwati H; Ackland J; Standish J; Justice F; Byars G; Lee KJ; Barnes GL; Bachtiar NS; Viska Icanervilia A; Boniface K; Bogdanovic-Sakran N; Pavlic D; Bishop RF; Kirkwood CD; Buttery JP; Soenarto Y
    N Engl J Med; 2018 Feb; 378(8):719-730. PubMed ID: 29466164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of human neonatal RV3 rotavirus vaccine (Bio Farma) in adults, children, and neonates in Indonesia: Phase I Trial.
    At Thobari J; Damayanti W; Haposan JH; Nirwati H; Iskandar K; Samad ; Fahmi J; Sari RM; Bachtiar NS; Watts E; Bines JE; Soenarto Y
    Vaccine; 2021 Jul; 39(33):4651-4658. PubMed ID: 34244006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterisation of rotavirus strains detected during a clinical trial of the human neonatal rotavirus vaccine (RV3-BB) in Indonesia.
    Cowley D; Nirwati H; Donato CM; Bogdanovic-Sakran N; Boniface K; Kirkwood CD; Bines JE
    Vaccine; 2018 Sep; 36(39):5872-5878. PubMed ID: 30145099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rotavirus specific maternal antibodies and immune response to RV3-BB rotavirus vaccine in central java and yogyakarta, Indonesia.
    Danchin MH; Bines JE; Watts E; Cowley D; Pavlic D; Lee KJ; Huque H; Kirkwood C; Nirwati H; At Thobari J; Dewi Satria C; Soenarto Y; Oktaria V
    Vaccine; 2020 Apr; 38(16):3235-3242. PubMed ID: 32160948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human Neonatal Rotavirus Vaccine (RV3-BB) Produces Vaccine Take Irrespective of Histo-Blood Group Antigen Status.
    Boniface K; Byars SG; Cowley D; Kirkwood CD; Bines JE
    J Infect Dis; 2020 Mar; 221(7):1070-1078. PubMed ID: 31763671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Live attenuated tetravalent (G1-G4) bovine-human reassortant rotavirus vaccine (BRV-TV): Randomized, controlled phase III study in Indian infants.
    Saluja T; Palkar S; Misra P; Gupta M; Venugopal P; Sood AK; Dhati RM; Shetty A; Dhaded SM; Agarkhedkar S; Choudhury A; Kumar R; Balasubramanian S; Babji S; Adhikary L; Dupuy M; Chadha SM; Desai F; Kukian D; Patnaik BN; Dhingra MS
    Vaccine; 2017 Jun; 35(28):3575-3581. PubMed ID: 28536027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early phase II trial of human rotavirus vaccine candidate RV3.
    Barnes GL; Lund JS; Mitchell SV; De Bruyn L; Piggford L; Smith AL; Furmedge J; Masendycz PJ; Bugg HC; Bogdanovic-Sakran N; Carlin JB; Bishop RF
    Vaccine; 2002 Jul; 20(23-24):2950-6. PubMed ID: 12126907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial.
    Groome MJ; Koen A; Fix A; Page N; Jose L; Madhi SA; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
    Lancet Infect Dis; 2017 Aug; 17(8):843-853. PubMed ID: 28483414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study.
    Omenaca F; Sarlangue J; Szenborn L; Nogueira M; Suryakiran PV; Smolenov IV; Han HH;
    Pediatr Infect Dis J; 2012 May; 31(5):487-93. PubMed ID: 22228231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, open-labelled, non-inferiority phase 4 clinical trial to evaluate the immunogenicity and safety of the live, attenuated, oral rotavirus vaccine, ROTAVAC® in comparison with a licensed rotavirus vaccine in healthy infants.
    Ella R; Babji S; Ciarlet M; Blackwelder WC; Vadrevu KM
    Vaccine; 2019 Jul; 37(31):4407-4413. PubMed ID: 31178377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral immunization with live Lactococcus lactis expressing rotavirus VP8 subunit induces specific immune response in mice.
    Marelli B; Perez AR; Banchio C; de Mendoza D; Magni C
    J Virol Methods; 2011 Jul; 175(1):28-37. PubMed ID: 21530589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-structural protein NSP2 induces heterotypic antibody responses during primary rotavirus infection and reinfection in children.
    Kirkwood CD; Boniface K; Richardson S; Taraporewala ZF; Patton JT; Bishop RF
    J Med Virol; 2008 Jun; 80(6):1090-8. PubMed ID: 18428132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.